Cholesterol epoxide hydrolase and cancer.

Abstract : Cholesterol epoxide hydrolase (ChEH) catalyzes the hydration of cholesterol-5,6-epoxides (5,6-EC) into cholestane-3β,5α,6β-triol. ChEH is a hetero-oligomeric complex called the anti-estrogen binding site (AEBS) comprising 3β-hydroxysterol-Δ(8)-Δ(7)-isomerase (D8D7I) and 3β-hydroxysterol-Δ(7)-reductase (DHCR7). D8D7I and DHCR7 regulate cholesterol biosynthesis, fetal development and growth, tumor cell differentiation and death. The un-reactivity of 5,6-EC toward nucleophiles has recently been demonstrated indicating that 5,6-EC are not alkylating and carcinogenic agents as first postulated. Here we discuss recent advances in the molecular characterization of ChEH, its potential role in cancer progression and resistance as well as the interest of inhibiting ChEH and to accumulate 5,6-EC which may contribute to the anti-tumor and chemopreventive action of ChEH inhibitors used in the clinic such as tamoxifen.
Type de document :
Article dans une revue
Current Opinion in Pharmacology, Elsevier, 2012, 12 (6), pp.696-703. 〈10.1016/j.coph.2012.07.007〉
Liste complète des métadonnées
Contributeur : Marc Poirot <>
Soumis le : vendredi 19 octobre 2012 - 09:38:08
Dernière modification le : jeudi 13 septembre 2018 - 01:00:33




Sandrine Silvente-Poirot, Marc Poirot. Cholesterol epoxide hydrolase and cancer.. Current Opinion in Pharmacology, Elsevier, 2012, 12 (6), pp.696-703. 〈10.1016/j.coph.2012.07.007〉. 〈inserm-00743463〉



Consultations de la notice